Xtrackers Russell 2000 UCITS ETF 1C is a equity ETF from Xtrackers tracking the Russell 2000 index through physical replication. Domiciled in Ireland and launched in 2015, the fund manages about 2.5 bn € and charges a TER of 0.30% — 30 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
Xtrackers Russell 2000 UCITS ETF 1C competes with 2 other products on the same index (Russell 2000): it ranks 1st by fund size and 2nd by ongoing cost, with a TER of 0.30% against a group median of 0.30%. It has been listed since 2015, 11 years of track record.
On a €10,000 investment the TER costs 30 € a year. The cheapest of the group is Invesco Russell 2000 UCITS ETF EUR at 0.25%, or 25 € on the same amount: a difference of 5 € every year, roughly 50 € over ten years before compounding.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 3.4% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| Moog Inc | 0.4% |
| Hut 8 Corp. Common Stock | 0.4% |
| ViaSat Inc | 0.4% |
| BrightSpring Health Services, Inc. Common Stock | 0.4% |
| Cytokinetics Inc | 0.3% |
| MaxLinear Inc | 0.3% |
| Argan Inc | 0.3% |
| UMB Financial Corporation | 0.3% |
| Jfrog Ltd | 0.3% |
| Riot Platforms, Inc. | 0.3% |
| Borsa Italiana | XRS2 | EUR |
| XETRA | XRS2 | EUR |
| Francoforte | XRS2 | EUR |
| London Stock Exchange | XRSG | GBX |
| London Stock Exchange | XRSU | USD |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.